Gilead Sciences, Inc. vs 10X Genomics Inc — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while 10X Genomics Inc trades at $59 (market cap $7.61B). The key difference: Gilead Sciences, Inc. is far larger — about 22.1× 10X Genomics Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| GILD | TXG | |
|---|---|---|
Market Cap | $168.35B | $7.61B |
Sector | Health | Health |
52-Week High | $155.80 | $58.57 |
52-Week Low | $110.56 | $11.34 |
Enterprise Value | $191.42B | $7.14B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →